Alzheimer's - Dementia, Author Interviews, Cannabis / 06.02.2026

Editor's note: Do Not Use these products alone or in combination without the specific guidance of your health are provider, due to risks of untoward side effects. THC/CBD and other cannabis products should not be used if you are pregnant, planning to become pregnant or nursing. Children should not be exposed to cannabis in any form. MedicalResearch.com Interview with: [caption id="attachment_72277" align="alignleft" width="200"]Chu Chen, PhDProfessor and Joe R. and Teresa Lozano Long Chair in Neural Physiology Department of Cellular and Integrative Physiology Center for Biomedical Neuroscience Joe R. and Teresa Lozano Long School of Medicine University of Texas at San Antonio Health Science Center San Antonio, TX 78229 Prof. Chu Chen[/caption] Chu Chen, PhD Professor and Joe R. and Teresa Lozano Long Chair in Neural Physiology Department of Cellular and Integrative Physiology Center for Biomedical Neuroscience Joe R. and Teresa Lozano Long School of Medicine University of Texas at San Antonio Health Science Center San Antonio, TX 78229 MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, yet no effective therapies currently exist to prevent, treat, or halt its progression. Cannabis has been used for thousands of years for both recreational and medicinal purposes; however, its therapeutic application has been limited by undesirable neurocognitive side effects, particularly impairments in learning and memory. Δ9-Tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis, has been shown to reduce amyloid-β (Aβ) pathology in animal models of AD, but at high doses (>5.0 mg/kg) it also disrupts synaptic function and impairs cognition. Research from our laboratory and others has demonstrated that Δ9-THC-induced deficits in long-term synaptic plasticity, learning, and memory are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid into pro-inflammatory prostaglandins. Notably, pharmacological inhibition or genetic deletion of COX-2 attenuates Δ9-THC-induced synaptic and cognitive impairments. Based on these findings, we proposed a combination (“cocktail”) therapy consisting of low-dose Δ9-THC and the anti-inflammatory drug celecoxib, a selective COX-2 inhibitor, as a potential therapeutic strategy for AD. This approach is designed to preserve the beneficial effects of Δ9-THC while minimizing its adverse neurocognitive effects and COX-2-mediated inflammatory responses.
Alzheimer's - Dementia, Author Interviews, Lipids, Vanderbilt / 18.01.2026

MedicalResearch.com Interview with: [caption id="attachment_72035" align="alignleft" width="200"]Leslie S. Gaynor, PhDClinical Neuropsychologist & Assistant Professor of Medicine Division of Geriatric Medicine Department of Medicine Vanderbilt University Medical Center Nashville, TN 37203 Dr. Gaynor[/caption] Leslie S. Gaynor, PhD Clinical Neuropsychologist & Assistant Professor of Medicine Division of Geriatric Medicine Department of Medicine Vanderbilt University Medical Center Nashville, TN 37203 MedicalResearch.com: What is the background for this study? Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.
Alzheimer's - Dementia, Author Interviews, Case Western / 25.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71888" align="alignleft" width="150"]Andrew A. Pieper M.D., Ph.D.Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center Dr. Pieper[/caption] Andrew A. Pieper M.D., Ph.D. Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center   MedicalResearch.com: What is the background for this study? Response: NAD+, a central cellular energy and signaling molecule, declines with age throughout the body, including the brain. When NAD+ falls below necessary levels, cells lose their ability to carry out essential maintenance and survival functions. We found that the NAD+ decline is more severe in brains from people with Alzheimer’s disease (AD) and in mouse models of AD, whereas brains of people with AD pathology but preserved cognition show gene-expression patterns consistent with maintained NAD+ homeostasis.
Alzheimer's - Dementia, Author Interviews, Diabetes, JAMA, Weight Research / 09.04.2025

MedicalResearch.com Interview with: [caption id="attachment_67848" align="alignleft" width="150"]Dr. Catriona Reddin MDFourth year Specialist Registrar in Geriatric Medicine  and an Irish Clinical Academic Training (ICAT) fellow University Hospital Galway, Galway, Ireland Dr. Reddin[/caption] Dr. Catriona Reddin MD Fourth year Specialist Registrar in Geriatric Medicine  and an Irish Clinical Academic Training (ICAT) fellow University Hospital Galway, Galway, Ireland   MedicalResearch.com: What is the background for this study? Response: Dementia is a leading cause of disability globally, which is projected to affect approximately 75 million people by 2030. Diabetes mellitus is a risk factor for dementia, it was unclear if glucose lower therapies reduce the risk of dementia. The research, a systematic review and meta-analysis of 26 clinical trials involving over 160,000 participants, found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—GLP-1Ras—was linked to a significant reduction.
Alzheimer's - Dementia, Author Interviews, Herpes Viruses / 08.01.2025

MedicalResearch.com Interview with: [caption id="attachment_65850" align="alignleft" width="150"]Dr. Or Shemesh PhDThe Harvey M. Krueger Family Center for Center for Nanoscience and Nanotechnology School of Pharmacy - Institute for Drug Research The Hebrew University of Jerusalem Dr. Or Shemesh[/caption] Dr. Or Shemesh PhD The Harvey M. Krueger Family Center for Center for Nanoscience and Nanotechnology School of Pharmacy - Institute for Drug Research The Hebrew University of Jerusalem MedicalResearch.com: What is the background for this study? Response: Our study investigated the connection between herpes simplex virus 1 (HSV-1) and Alzheimer's disease (AD) pathologies. We explored how HSV-1 proteins are present in the brains of individuals with AD and examined their interactions with tau, a key protein in AD pathology. MedicalResearch.com: What are the main findings? Response:  The main finding is that tau, traditionally seen as detrimental, might initially act as a protective response to HSV-1 by reducing neuronal death through an antiviral innate immunity pathway called cGAS-STING . Over time, this (initially beneficial) antiviral response of tau can manifest as the well established tau toxicity in Alzheimer's disease.
Alzheimer's - Dementia, Infections / 19.12.2024

MedicalResearch.com Interview with: [caption id="attachment_65601" align="alignleft" width="200"]Benjamin Readhead PhDResearch Associate Professor Banner Neurodegenerative Disease Research Center Biodesign Institute Arizona State University Dr. Readhead[/caption] Benjamin Readhead PhD Research Associate Professor Banner Neurodegenerative Disease Research Center Biodesign Institute Arizona State University MedicalResearch.com: What is the background for this study? Response: Our study describes a surprising link between an intestinal infection with a common virus, human cytomegalovirus (HCMV), and the development of Alzheimer’s in a subset of people with the disease. In a study published earlier this year in the journal Nature Communications, we found that research participants with Alzheimer’s disease were more likely than those without it to harbor a particular immune cell type (“CD83(+) microglia”) in their brains. While trying to uncover what might be driving the presence of these CD83(+) microglia, we discovered an antibody (IgG4) in the intestine of these same subjects that were suggestive of the possibility that some kind of infection might contribute to this form of the disease.
Alzheimer's - Dementia, Author Interviews, Biomarkers / 11.12.2024

MedicalResearch.com Interview with: [caption id="attachment_65442" align="alignleft" width="180"]Alberto J. Espay, MD, MSc, FAANProfessor of Neurology Director and Endowed Chair Gardner Family Center for Parkinson's disease and Movement Disorders University of Cincinnati Academic Health Center Prof. Espay[/caption] Alberto J. Espay, MD, MSc, FAAN Professor of Neurology Director and Endowed Chair Gardner Family Center for Parkinson's disease and Movement Disorders University of Cincinnati Academic Health Center MedicalResearch.com: What is the background for this study? What are the main findings Response:  Because aducanumab, lecanemab, and donanemab were only in a minority of anti-amyloid treatments showing a benefit, I was interested in finding out what makes them special. It turns out that they not only clean the brain from amyloid, like other monoclonal anti-Aβ antibodies, but they also increase Aβ42 in the spinal fluid, which is a measure of the normal protein in the brain. Everyone with Alzheimer’s has low Aβ42 levels because this protein clumps into amyloid plaques. I tested the hypothesis that increasing Aβ42 could explain the cognitive outcomes at least as well as decreasing amyloid, and that’s exactly what we found. This suggests that restoring the normal protein levels, Aβ42, may explain why some anti-amyloid treatments (presumably those that increased those levels the most) come with benefits.
Alzheimer's - Dementia, Author Interviews, Cost of Health Care, Medicare, UCLA / 15.10.2024

MedicalResearch.com Interview with: [caption id="attachment_64014" align="alignleft" width="150"]Frank F. Zhou  |  he/himMD Candidate, Class of 2025 David Geffen School of Medicine at UCLA Frank F Zhou[/caption] Frank F. Zhou  |  he/him MD Candidate, Class of 2025 David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? What is Lecanemab used for?  How is it given to patients? Response: Lecanemab is a new infusion therapy for Alzheimer's disease. Its dosing is based on each patient's body weight (10 mg/kg every two weeks), but the drug is only available in 500 mg and 200 mg single-use vials, meaning that any leftover drug in vials must be thrown away. Given that lecanemab is expected to cost Medicare billions of dollars each year, we hypothesized that discarded drug could result in significant wasteful spending.
Alzheimer's - Dementia, Author Interviews / 29.08.2024

stethoscope-alzheimers-article

Alzheimer’s disease is the most common condition that leads to a gradual loss of memory and thinking skills. It’s marked by the buildup of plaques and tangles in the brain. It’s one of many different areas where Anavex Life Sciences is focusing its research as part of its mission to develop effective therapeutics for neurodegenerative disorders. In 1984, researchers discovered that a protein called amyloid beta is a key part of the plaques that aggregate in the brain. This led to the theory that Aβ is central to Alzheimer’s, known as the "amyloid cascade hypothesis." Since then, most Alzheimer’s treatments have targeted Aβ. However, many of these treatments have failed in clinical trials, leading to questions about this approach. Aβ is created from a larger protein called amyloid precursor protein through a series of steps involving different enzymes. Normally, APP is processed in a way that prevents the formation of Aβ. However, under certain conditions, the enzymes BACE1 and γ-secretase cut APP in a way that produces Aβ. Once formed, Aβ needs to be cleared from the brain to prevent harmful buildup. Aβ clearance involves several pathways, including enzyme degradation, transport across the blood-brain barrier, and removal through the brain’s fluid drainage systems. The blood-brain barrier is a network of cells that controls what enters and leaves the brain. Specific proteins help move Aβ out of the brain, but for those with Alzheimer’s, these proteins don’t work as well, leading to Aβ accumulation. Genetic studies show that Aβ buildup plays a significant role in the disease. For example, people with Down syndrome, who have an extra copy of the APP gene, often develop Alzheimer’s. Mutations in genes related to APP processing can also cause early-onset Alzheimer’s, while certain mutations can protect against it. Both genetic and lifestyle factors, like diabetes and lack of exercise, can increase Aβ production or hinder its clearance. Despite setbacks, there are promising developments in Aβ-based therapies. Aducanumab, an antibody that targets Aβ, was approved by the FDA for its ability to reduce Aβ plaques in early Alzheimer’s patients. Another antibody, donanemab, has shown even better results in clearing Aβ from the brain. Similarly, lecanemab, which targets soluble forms of Aβ, has been shown to reduce amyloid levels and improve cognitive function. Another drug, Anavex 2-73 (blarcamesine), has shown potential in reducing Alzheimer’s symptoms and brain changes in animal studies and a late stage human trial. Blarcamesine is a formulation of Anavex, a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease and other central nervous system disorders. These advances offer new hope that targeting Aβ could still be a valid approach to treating Alzheimer’s.
Alzheimer's - Dementia, Social Issues / 27.06.2024

Caring for a loved one with dementia at home can be challenging. As a caregiver, it is important to educate yourself on strategies to provide the best care while also taking care of your own wellbeing. Here are some helpful tips for caregivers managing dementia care at home.

Understand the Stages of Dementia

The first step is understanding the different stages of dementia - mild, moderate and severe. Knowing what stage your loved one is in will help you plan care accordingly. In the early stages, maintaining independence may be possible with reminders and the help of home caregivers such as home care services in Greensboro, NC. In the later stages, full-time care is usually required for basic activities like eating, bathing and dressing. Understanding the dementia stage will help you adapt care needs.

caregivers-eldercare_pexels-kampus-7551618Create a Safe, Comfortable Environment

As dementia progresses, people can become disoriented and confused. To limit risks, make sure your home environment is safe and comfortable. Reduce clutter, improve lighting, install handrails and non-slip mats in bathrooms. Lock away medications and toxic products. Consider monitoring systems like motion sensors if the person wanders. Also, ensure favorite belongings and familiar objects are around to provide comfort.
Alzheimer's - Dementia, Author Interviews, JAMA / 22.06.2024

MedicalResearch.com Interview with: [caption id="attachment_62050" align="alignleft" width="150"]Mabel Seto, PhDHarvard Aging Brain Study, Department of Neurology Massachusetts General Hospital, Center for Alzheimer Research and Treatment Department of Neurology Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts Vanderbilt Memory and Alzheimer’s Center Vanderbilt University Medical Center Nashville, Tennessee Dr. Seto[/caption] Mabel Seto, PhD Harvard Aging Brain Study, Department of Neurology Massachusetts General Hospital, Center for Alzheimer Research and Treatment Department of Neurology Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts Vanderbilt Memory and Alzheimer’s Center Vanderbilt University Medical Center Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: The background for this study is that individuals with a family history of Alzheimer’s disease (i.e., one or more first-degree relatives) have a higher risk for the disease than individuals that don’t have a family history. Previous studies suggested a preferential maternal inheritance of AD, though they were limited in sample size and statistical power. In our study, we wanted to focus on a larger, cognitively unimpaired sample. Using data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, a randomized clinical trial aimed at AD prevention, we examined the relationship between a parental history of significant memory impairment as a proxy for AD (as some individuals may not have pursued formal diagnosis) and amyloid-beta burden in the offspring.
Alzheimer's - Dementia, Author Interviews, Brigham & Women's - Harvard, JAMA, Nutrition / 07.05.2024

MedicalResearch.com Interview with: [caption id="attachment_61650" align="alignleft" width="200"]Marta Guasch-Ferré, PhDAssociate Professor and Deputy Head of Section, Section of Epidemiology University of Copenhagen  Group Leader, Novo Nordisk Foundation Center for Basic Metabolic Research  Adjunct Associate Professor, Department of Nutrition Harvard TH Chan School of Public Health  Dr. Guasch-Ferré[/caption] Marta Guasch-Ferré, PhD Associate Professor and Deputy Head of Section, Section of Epidemiology University of Copenhagen Group Leader, Novo Nordisk Foundation Center for Basic Metabolic Research Adjunct Associate Professor, Department of Nutrition Harvard TH Chan School of Public Health MedicalResearch.com: What is the background for this study? Response:  Olive oil is rich in monounsaturated fats and contains compounds with antioxidant activity that may play a protective role for the brain. Olive oil as part of a Mediterranean diet appears to have a beneficial effect against cognitive decline. Higher olive oil intake was previously associated with a lower risk of cardiovascular disease and mortality. But its association with dementia mortality was unknown.
Alzheimer's - Dementia, Author Interviews / 02.05.2024

MedicalResearch.com Interview with: [caption id="attachment_61640" align="alignleft" width="110"]Dr. Li Gan PhDBurton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases Brain and Mind Research Institute Weill Cornell Medical College Dr. Li Gan[/caption] Dr. Li Gan PhD Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases Brain and Mind Research Institute Weill Cornell Medical College [caption id="attachment_61627" align="alignleft" width="150"]Shiaoching Gong PhD Helen and Robert Appel Alzheimer’s Disease Institute Feil Family Brain and Mind Research Institute Weill Cornell Medicine, New York, NY Dr. Shiaoching Gong[/caption] Shiaoching Gong PhD Helen and Robert Appel Alzheimer’s Disease Institute Feil Family Brain and Mind Research Institute Weill Cornell Medicine, New York, NY MedicalResearch.com: What is the background for this study? Would you describe the process of making these neurons? Response: Primary tauopathies are a group of progressive neurodegenerative diseases characterized by the pathological aggregation of 3R or 4R tau protein in neurons and/or glial cells, where 4R tauopathies are more common primary tauopathies. The exact pathological mechanisms remain elusive. There are currently no therapies available that can halt or reverse the spread of tau aggregates since the drug effects found in animal models are not always reproduced in human clinical trials. The development of tau therapies from human cells have become urgently needed. Induced human pluripotent stem cells (iPSCs) offer a unique model to better understand pathological mechanisms underlying human diseases and to develop human cell-based therapy. However, a major challenge to study 4R tauopathy is iPSC-derived neurons express very low levels of 4R Tau isoforms making it difficult to study 4R tauopathy and the mutations located in 4R Tau. To address this need, we designed and engineered a robust human iPSC 4R tauopathy model using CRISPR/Cas9 technology. We first introduced specific mutations at the intron-exon 10 junctions and silent mutations within exon 10 to promote exon 10 inclusion, leading the increase of 4R isoforms expression in iPSC-derived neurons. Frontotemporal Dementia (FTD) mutation, P301S located in exon 10 is highly aggregation prone. To generate this human disease 4R tauopathy model, we then introduced this mutation to 4R iPSC to make it a 4RP301S iPSC line.
Alzheimer's - Dementia, Author Interviews, JAMA, UC Davis / 25.03.2024

MedicalResearch.com Interview with: [caption id="attachment_61484" align="alignleft" width="150"]Charles DeCarli, MD, FAAN, FAHAVictor and Genevieve Orsi Chair in Alzheimer's Research Distinguished Professor of Neurology Director, Alzheimer's Disease Research Center and Imaging of Dementia and Aging (IDeA) Laboratory Department of Neurology and Center for Neuroscience University of California at Davis Sacramento, CA  95817 Dr. DeCarli[/caption] Charles DeCarli, MD, FAAN, FAHA Victor and Genevieve Orsi Chair in Alzheimer's Research Distinguished Professor of Neurology Director, Alzheimer's Disease Research Center and Imaging of Dementia and Aging (IDeA) Laboratory Department of Neurology and Center for Neuroscience University of California at Davis Sacramento, CA  95817   MedicalResearch.com: What is the background for this study? Response: The overall health of the U.S. population has improved dramatically over the last 100 years, Individuals are also living longer resulting in an increasing percentage of the population at risk for Alzheimer’s disease and related dementias (ADRD).  Recent data from the Framingham Heart study, however, finds that dementia incidence may be declining.  While many factors such as greater educational achievement and medical management of vascular risk factors may explain part of this effect, early life environmental differences also likely contribute.
Alzheimer's - Dementia, Author Interviews, Weight Research / 28.11.2023

MedicalResearch.com Interview with:

[caption id="attachment_61098" align="alignleft" width="160"]Mahsa Dolatshahi, M.D., M.P.H.Post-doctoral research fellow Mallinckrodt Institute of Radiology (MIR) Washington University School of Medicine St. Louis Dr. Dolatshahi[/caption] Mahsa Dolatshahi, M.D., M.P.H. Post-doctoral research fellow Mallinckrodt Institute of Radiology (MIR) Washington University School of Medicine St. Louis MedicalResearch.com: What is the background for this study? Response: Obesity at midlife is recognized as a risk factor for developing Alzheimer disease decades afterwards. However, body mass index on its own does not adequately represent the risks associated with obesity. In this study, we went beyond BMI and considered anatomical distribution of body fat, including the metabolically active visceral fat in the belly, and showed its association with Alzheimer pathology in the form of amyloid proteins. In addition, visceral fat along with obesity and insulin resistance were associated with thinning of brain cortex, as early as midlife.
Alzheimer's - Dementia, Author Interviews, Genetic Research, JAMA, Stanford / 07.11.2023

MedicalResearch.com Interview with: [caption id="attachment_61020" align="alignleft" width="125"]MedicalResearch.com Interview with:Michael E. Belloy, PhD Department of Neurology and Neurological Sciences Stanford University, Stanford, California Dr. Belloy[/caption] Michael E. Belloy, PhD Department of Neurology and Neurological Sciences Stanford University, Stanford, California MedicalResearch.com: What is the background for this study? Response: Apolipoprotein E (APOE)*2 and APOE*4 are, respectively, the strongest protective and risk-increasing, genetic variants for late-onset Alzheimer disease. As such, one’s APOE genotype is highly relevant towards clinical trial design and Alzheimer’s disease research. However, most insights so far are focused on the associations of these APOE genotypes with Alzheimer’s disease risk in non-Hispanic white individuals. One important aspect of our work is that we really increased sample sizes for non-Hispanic Black, Hispanic, and East Asian individuals, so that we now have better understanding of the associations of APOE genotypes with Alzheimer’s disease risk in these groups. In complement, we also did the largest investigation to date on the role of ancestry on the associations of APOE genotypes with Alzheimer’s disease risk. The scale of our study was thus a critical factor in generating novel insights.
Alzheimer's - Dementia, Author Interviews, Baylor College of Medicine Houston / 22.10.2023

MedicalResearch.com Interview with: [caption id="attachment_60949" align="alignleft" width="200"]David B. Corry, M.D.Professor of Pathology & Immunology and Medicine Vice Chair for Immunology Department of Pathology & Immunology Biology of Inflammation Center Dan L. Duncan Comprehensive Cancer Center   Clarence and Irene H. Fulbright Chair in Pathology Baylor College of Medicine Michael E. Debakey VA Medical Center Dr. Corry[/caption] David B. Corry, M.D. Professor of Pathology & Immunology and Medicine Vice Chair for Immunology Department of Pathology & Immunology Biology of Inflammation Center Dan L. Duncan Comprehensive Cancer Center   Clarence and Irene H. Fulbright Chair in Pathology Baylor College of Medicine Michael E. Debakey VA Medical Center MedicalResearch.com: What is the background for this study? Can candida species cross the blood brain barrier? Response: We showed earlier (2019) that the common fungus Candida albicans can enter the brain from the blood. That earlier study was in turn inspired by the finding of another research group that had found Candida in the brains of persons suffering from Alzheimer’s Disease and related dementing illnesses.
Alzheimer's - Dementia, Author Interviews, Genetic Research / 14.06.2023

MedicalResearch.com Interview with: [caption id="attachment_60501" align="alignleft" width="150"]Alexandra M Whiteley PhDDepartment of Biochemistry University of Colorado Boulder Boulder, Colorado Dr. Whiteley[/caption] Alexandra M Whiteley PhD Department of Biochemistry University of Colorado Boulder Boulder, Colorado MedicalResearch.com: What is the background for this study? Response: My laboratory was interested in understanding how UBQLN2 maintains cellular health. Ubiquilins facilitate protein degradation, but the precise proteins that they help to break down were not well understood. UBQLN2 is of particular interest because mutations in the UBQLN2 gene lead to a familial form of ALS. This project, which was published in eLife this year, stems from work that was published when I was a postdoctoral researcher at Harvard Medical School, where we found a link between UBQLN2 and the virus-like protein PEG10. Now at the University of Colorado, Boulder, my laboratory has focused on trying to understand this connection between the two proteins, and how PEG10 could contribute to ALS.
Alzheimer's - Dementia, Author Interviews, Biomarkers, University of Pittsburgh / 31.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60470" align="alignleft" width="150"]Bruna Bellaver PhDPostdoctoral associate Department of Psychiatry University of Pittsburgh Dr. Bellaver[/caption] Bruna Bellaver PhD Postdoctoral associate Department of Psychiatry University of Pittsburgh Tharick Pascoal, MD, Ph.D. Neurologist and assistant professor of Neurology and Psychiatry University of Pittsburgh School of Medicine. MedicalResearch.com: What is the background for this study? Response: Amyloid-β (Aβ) deposition is considered one of the markers of Alzheimer’s disease pathology in the brain. The sequential order of this cascade includes the development of tau pathology and consequent cognitive decline. However, many people with Aβ deposition in the brain do not progress in the disease, suggesting that other biological processes are playing a role in these pathological events. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. We found that, in cognitively healthy individuals, Aβ is associated with tau pathology only in individuals with increased astrocyte reactivity.
Alzheimer's - Dementia, Author Interviews, Lifestyle & Health, Nutrition, Vegetarians / 30.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60452" align="alignleft" width="150"]JoAnn E. Manson, MD, DrPH, MACPChief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School Boston, Massachusetts  02215 Dr. Manson[/caption] JoAnn E. Manson, MD, DrPH, MACP Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School Boston, Massachusetts  02215   MedicalResearch.com: What is the background for this study?  Any particular types of vitamins, ie with/without iron etc? Response: Preserving memory and cognitive health is a high priority for most mid-life and older adults.  However, few strategies have been rigorously tested in randomized clinical trials and shown to have cognitive benefits. Nutritional approaches hold promise because the brain requires several nutrients for optimal health, and deficiencies in one or more of these nutrients may lead to accelerated memory loss and cognitive decline. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a large-scale nation-wide randomized trial of multivitamins and cocoa flavanols had recently reported that multivitamins slowed global cognitive decline and memory loss (in COSMOS-Mind). The current study was a 2nd parallel trial, a collaboration between Brigham and Women’s Hospital and Columbia University, looking at a web-based assessment of the role of a  standard multivitamin and of cocoa flavanols in slowing age-related memory loss. The report in AJCN is on the multivitamin-cognition findings. The multivitamin tested was Centrum silver for adults (without iron).
Alzheimer's - Dementia, Author Interviews, Biomarkers, JAMA, MRI / 22.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60448" align="alignleft" width="128"]Ruben Smith MD, PhDAssociate professor at Clinical Memory Research Division of Neurology Lund University Dr. Smith[/caption] Ruben Smith MD, PhD Associate professor at Clinical Memory Research Division of Neurology Lund University   MedicalResearch.com: What is the background for this study? Response: Since a few years it has become possible to visualize tau pathology in Alzheimer’s Disease (AD) using positron emission tomography (PET). The tau-PET radiotracer Flortaucipir (Tauvid) was recently approved by the US Food and Drug Administration as an AD diagnostic tool. Since PET imaging is costly and exposes the patient to radioactivity we wanted to study the added clinical value of tau-PET in the diagnostic work-up of patients with cognitive symptoms, before widespread implementation in clinical practice.
Alzheimer's - Dementia, Author Interviews, Cost of Health Care, JAMA, UCLA / 20.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60418" align="alignleft" width="100"]Julia Cave ArbanasProject Manager and Julia Cave Arbanas[/caption] Julia Cave Arbanas Project Manager and     John N. Mafi, MD, MPH Associate Professor of Medicine General Internal Medicine & Health Services Research David Geffen School of Medicine at UCLAJohn N. Mafi, MD, MPH Associate Professor of Medicine General Internal Medicine & Health Services Research David Geffen School of Medicine at UCLA   MedicalResearch.com: What is the background for this study? What is lecanemab used for and how well does it work? Response: Lecanemab is a treatment for mild cognitive impairment and mild dementia that was approved in January 2023 as part of the Food and Drug Administration’s (FDA) accelerated approval program. The results from a recent phase 3 clinical trial show a modest clinical benefit: the rate of cognitive decline by 27% in an 18-month study involving participants experiencing the early stage of Alzheimer’s, with an 0.45-point absolute difference in cognitive testing scores. However, due to the risk of brain swelling and bleeding (also known as amyloid-related imaging abnormalities), treatment with lecanemab involves frequent MRIs and neurology or geriatrics appointments to monitor for these abnormalities, which can be life threatening. So far, three patient deaths have potentially been tied to lecanemab. It is likely that the FDA will grant is lecanemab traditional approval later this year, prompting Medicare to reconsider its current coverage restrictions and potentially enabling widespread use.
Alzheimer's - Dementia, Author Interviews, JAMA, Mediterranean Diet, Mental Health Research / 08.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60406" align="alignleft" width="139"]Yuan Changzheng ScD, MSc, B.M.Research Professor Doctoral supervisor, School of Medicine Zhejiang University School of Public Health Adjunct assistant professor Harvard T.H. Chan School of Public Health Dr. Yuan Changzheng[/caption] Yuan Changzheng ScD, MSc, B.M. Research Professor Doctoral supervisor, School of Medicine Zhejiang University School of Public Health Adjunct assistant professor Harvard T.H. Chan School of Public Health   MedicalResearch.com: What is the background for this study? Response: The prevention of all-cause dementia is important as it poses substantial burdens on healthcare systems and threatens the well-being of older adults, and lack of effective treatments makes its prevention crucial. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet is a hybrid of the Mediterranean diet and the DASH diet, and it emphasizes natural plant-based foods, limited intake of certain animal foods and foods high in saturated fat and encourages consumption of berries and green leafy vegetables rich in vitamins and antioxidants. The MIND diet has previously been associated with lower risk of Alzheimer's disease and slower cognitive decline but few studies have examined its association with all-cause dementia or AD with inconclusive results.
Alzheimer's - Dementia, Author Interviews, Brigham & Women's - Harvard, Gender Differences, JAMA, Menopause / 03.04.2023

MedicalResearch.com Interview with: [caption id="attachment_60274" align="alignleft" width="150"]Rachel Buckley, PhD​Assistant Professor Department of Neurology Massachusetts General Hospital/Harvard Medical School Dr. Buckley[/caption] Rachel Buckley, PhD ​Assistant Professor Department of Neurology Massachusetts General Hospital/Harvard Medical School MedicalResearch.com: What is the background for this study? Response: While a fair amount of studies have focused on the effects of menopause and hormone therapy on risk of dementia, far fewer studies have tested their association with the biology of Alzheimer’s disease, namely amyloid and tau. This is critical to know given that it still remains unclear what might be the driving mechanism of the menopause transition on risk for dementia. This is what our study set out to investigate. This study is one of the first to report a link between women’s age at menopause and tau in the brain, which we measured with positron emission tomography neuroimaging. We found that in multiple areas of the brain that tend to be most likely to show higher tau in women than men, women with earlier age at menopause and elevated levels of amyloid showed higher levels of tau than those who reported an average age at menopause (~50 years in the United States). Women who reported premature menopause (<40 years at menopause onset) exhibited a much higher risk of tau in the brain. This supports the notion that longer exposure to estrogen throughout life might be protective against Alzheimer’s disease.
Alzheimer's - Dementia / 03.03.2023

Dementia is a condition that affects many older adults aged 65 years and older but is increasingly being diagnosed in much younger people. It is a tragic disease as the personality of the sufferer changes, they struggle to identify close family members, and there is a profoundly sad loss of dignity as the disease progresses. Medical researchers are very active in undertaking experiments to find better ways of early diagnosis and treating patients more effectively. We look at the more recent research in this regard.

Improved Digital Markers

Scientists have found a new method to predict dementia before its onset or while it is still mild. This allows those who are positively identified to make lifestyle changes to stay healthy for longer and to begin preparing for special care when they can no longer look after themselves. The research tests comprised a study of driving behaviors. This was a longitudinal study. It had a 96% accuracy and considered 200 driving elements. Just under 3000 test subjects participated in the study, which took place in five US states. All the participants were still driving their own vehicles as a way of retaining their independence as they entered the older age stages of life, with everyone being between 65 and 79 years of age. Eighty-five percent of this age group were found to still be driving at this stage of life. None had signs of cognitive decline. Follow-up of the participants took place three years after the testing phase. Sixty-one participants had gone on to develop Alzheimer’s disease, some cognitive decline, or other types of dementia. The researchers compared their results against two other popular methods (logistic regression and random forests) of predicting dementia and found that their test had a 6-10% greater accuracy than the rest. Two aspects of driving that were especially useful for predicting future dementia were how many times drivers braked hard with 0.4 g or greater deceleration and the ratio of right and left turns. Regarding the latter, older people found it less risky to turn right rather than left. Early warning of possible dementia later in life is essential to preparing for increasing levels of care, from overnight, to 24/7. Check out this guide if you want to know more about what is overnight care. Many dementia patients with mild impairment may start with this form of assistance. A bit of help when needed can allow the person to store their energy for greater independence in intimate activities like bathing.
Aging, Alzheimer's - Dementia, Author Interviews, Supplements / 01.03.2023

MedicalResearch.com Interview with: [caption id="attachment_60115" align="alignleft" width="125"]Christopher R. Martens PhDAssistant Professor Director, Delaware Center for Cognitive Aging Research Department of Kinesiology & Applied Physiology University of Delaware Newark, DE Dr. Martens[/caption] Christopher R. Martens PhD Assistant Professor Director, Delaware Center for Cognitive Aging Research Department of Kinesiology & Applied Physiology University of Delaware Newark, DE MedicalResearch.com: What is the background for this study? Response: One of the main issues with Alzheimer's disease is an impaired ability to make energy in the brain. NAD+ is critically involved in the creation of energy within cells and there is strong evidence that nicotinamide riboside (NR), a precursor to NAD+, can restore brain function in mice that exhibit similar characteristics as people with Alzheimer's disease. We had previously studied the effects of NR in healthy older adults and wanted to see whether it is even capable of getting into brain tissue. We used remaining blood samples from our original study and measured the amount of NAD+ within tiny "vesicles" in the blood that we are quite confident originated from the brain and other neural tissue
Alzheimer's - Dementia, Author Interviews, Genetic Research, Race/Ethnic Diversity, Stanford / 21.02.2023

MedicalResearch.com Interview with: [caption id="attachment_60059" align="alignleft" width="125"]Yann Le Guen, Ph.D.Assistant Director, Computational Biology Quantitative Sciences Unit Stanford Medicine Dr. Yann Le Guen[/caption] Yann Le Guen, Ph.D. Assistant Director, Computational Biology Quantitative Sciences Unit Stanford Medicine MedicalResearch.com: What is the background for this study? Response: Apart from aging, the strongest contributing factor for late-onset Alzheimer’s disease is a specific allele of the APOE gene, which has three common alleles E2, E3, and E4. While E3 is the most common and considered as the reference, E2 is associated with decreased Alzheimer’s disease risk and E4 is associated with increased Alzheimer’s disease risk. Notably the prevalence of E4 among Alzheimer’s patient is high with about 60% of these carrying at least one E4 allele, while solely about 30% Americans carry one E4 allele. It’s worth emphasizing that individuals with an E4/E4 genotype have an exponential increased in their risk to develop AD (10 times as likely than the reference E3/E3 genotype), and individuals with an E3/E4 genotype have an intermediate risk. Though, most studies of Alzheimer’s disease genetic have been focused on European ancestry, this is beginning to change thanks to NIH’s efforts to fund more studies in non-European ancestry individuals. Our study built on these recent efforts to assess the Alzheimer disease risk associated with an APOE variant (R145C) present in about ~4% African Americans, but extremely rare in Europeans.
Thank you for visiting MedicalResearch.com Senior Editor, Marie Benz MD. For more information please email: info@MedicalResearch.com

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.